Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

ESMO MCBS  1000x150

The ESMO-MCBS Scorecards provides a centralised location of cancer medicines that have been scored and published by ESMO.

It includes all cancer medicines approved by the European Medicines Agency (from January 2016) and the US Food and Drug Administration (from January 2020).

ESMO-MCBS Scores
Number of studies
Non-curative setting
5 20
4 105
3 140
2 36
1 21
Curative setting
A 41
C 3
ESMO-MCBS Scores by tumour type
Non-curative setting
Brain Tumours 2
Breast Cancer 34
Central Nervous System Malignancies 1
Endocrine Tumours 20
Gastrointestinal Cancers 59
Genitourinary Cancers 54
Gynaecological Malignancies 32
Head and neck cancer 9
Melanoma 21
RET fusion-positive tumours 1
Refractory NTRK fusion–positive cancers 2
Sarcoma 9
Skin Cancers 6
TMB-H solid tumours 1
Thoracic Malignancies 70
dMMR/MSI-H solid tumours 1
Curative setting
Brain Tumours 0
Breast Cancer 7
Central Nervous System Malignancies 1
Endocrine Tumours 0
Gastrointestinal Cancers 15
Genitourinary Cancers 3
Gynaecological Malignancies 0
Head and neck cancer 0
Melanoma 11
RET fusion-positive tumours 0
Refractory NTRK fusion–positive cancers 0
Sarcoma 2
Skin Cancers 1
TMB-H solid tumours 0
Thoracic Malignancies 4
dMMR/MSI-H solid tumours 0

The ESMO-MCBS Scorecards

The ESMO-MCBS Scorecards allows you to filter either by Agent, Tumour or Score giving priority to different criteria such as Agent and Tumour Type and Tumour sub-type and Tumour sub-group in the Curative or Non-curative setting. This content will be updated regularly and communicated to ESMO Members.

Evaluation form 1  For new approaches to adjuvant therapy or new potentially curative therapies
Evaluation form 2a For therapies that are not likely to be curative with primary endpoint of OS with separate sheets for:
Evaluation form 2b For therapies that are not likely to be curative with primary endpoint PFS with separate sheets for:
Evaluation form 2c  For therapies that are not likely to be curative with primary endpoint other than OS or PFS or equivalent (non-inferiority) studies
Evaluation form 3  For single-arm studies in “orphan diseases” and for diseases with “high unmet need” when primary outcome is PFS or ORR.
Quality of Life Checklist To evaluate ESMO-MCBS score adjustments based on quality of life

My watchlist

    Tested Agent(s) Combined Agent(s) Control Arm Treatment Setting Tumour Type Tumour Sub-type Tumour Sub-group Trial Name Ref. Score Scorecard Scorecard
    Enfortumab vedotin - Single arm (Phase II) Patients with locally advanced or metastatic UC who are ineligible for cisplatin-containing ChT and have previously received ≥1 prior lines of therapy Genitourinary Cancers Urothelial Carcinoma - EV-201 - Cohort 2
    3

    PRELIMINARY SCORE

    • OS
      6

    ADJUSTMENTS

    FINAL SCORE

    • F1
      3
    Erdafitinib - Single arm (Phase II) Locally advanced or metastatic urothelial carcinoma with susceptible FGFR3 or FGFR2 genetic alterations and disease progression during/after ≥1 prior platinum-containing ChT Genitourinary Cancers Urothelial Carcinoma FGFR3 or FGFR2 genetic alterations BLC2001
    1

    PRELIMINARY SCORE

    • OS
      7

    ADJUSTMENTS

    FINAL SCORE

    • F1
      5
    Pembrolizumab - Single arm (Phase II) Locally advanced or metastatic UC in adults who are not eligible for cisplatin-containing ChT and whose tumours express PD-L1 with a CPS ≥10 Genitourinary Cancers Urothelial Carcinoma PD-L1 CPS ≥10% MK-03475-052/KEYNOTE-052
    3

    PRELIMINARY SCORE

    • OS
      6

    ADJUSTMENTS

    FINAL SCORE

    • F1
      3
    Pembrolizumab - Investigator’s choice of ChT (paclitaxel, docetaxel or vinflunine) Locally advanced or metastatic UC in adults who have received prior platinum-containing ChT Genitourinary Cancers Urothelial Carcinoma - MK-3475-045/KEYNOTE-045
    4

    PRELIMINARY SCORE

    • OS
      5

    ADJUSTMENTS

    FINAL SCORE

    • F1
      2
    Nivolumab - Placebo Adjuvant therapy for adult patients with oesophageal or gastroesophageal junction cancer who have residual pathologic disease following prior neoadjuvant chemoradiotherapy Gastrointestinal Cancers Oesophageal or gastroesophageal carcinoma - CheckMate 577
    A

    ADJUSTMENTS

    FINAL SCORE

    • F1
      1
    Sotorasib - Single arm Treatment of adults with advanced non-small cell lung cancer with KRAS G12C mutation and who have progressed after at least one prior line of systemic therapy Thoracic Malignancies Non-small-cell Lung Cancer KRAS G12C mutated CodeBreaK 100
    3

    PRELIMINARY SCORE

    • OS
      6

    ADJUSTMENTS

    FINAL SCORE

    • F1
      3
    Cemiplimab - Single arm (Phase II) Treatment of basal cell carcinoma (laBCC or mBCC) who have progressed on or are intolerant to a hedgehog pathway inhibitor (HHI) Skin Cancers Basal Cell Carcinoma - Study 1620
    3

    PRELIMINARY SCORE

    • OS
      6

    ADJUSTMENTS

    FINAL SCORE

    • F1
      3
    Nivo/Ipi (nivolumab and ipilimumab) - Single arm (Phase II) Adult patients with MMR-deficient or MSI-high mCRC after prior fluoropyrimidine-based combination ChT Gastrointestinal Cancers Colorectal Cancer dMMR or MSI-H CheckMate142
    3

    PRELIMINARY SCORE

    • OS
      6

    ADJUSTMENTS

    FINAL SCORE

    • F1
      3
    Pemetrexed Cisplatin Cisplatin In combination with cisplatin for the treatment of chemotherapy naïve patients with unresectable malignant pleural mesothelioma Thoracic Malignancies Pleural mesothelioma - EMPHACIS
    3

    PRELIMINARY SCORE

    • OS
      6

    ADJUSTMENTS

    FINAL SCORE

    • F1
      3
    Lenvatinib Pembrolizumab Sunitinib Treatment of adults with advanced renal cell carcinoma in combination with pembrolizumab as first-line treatment Genitourinary Cancers Renal cell cancer - CLEAR
    4

    PRELIMINARY SCORE

    • OS
      6

    ADJUSTMENTS

    FINAL SCORE

    • F1
      2

    This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

    For more detailed information on the cookies we use, please check our Privacy Policy.

    Customise settings
    • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.